Category: Prescription Drugs
Global Prescription Drugs
-
Human Reproductive Technologies
... by 2030, growing at a CAGR of 2.3% over the analysis period 2023-2030. Contraceptive Drugs & Devices, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$22.0 ... Read More
-
Bipolar Disorder Therapeutics
... by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by ... Read More
-
Antidepressants
... of 2.5% over the analysis period 2023-2030. Antidepressants market for Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end ... Read More
-
Ophthalmic Pharmaceutical Drugs
... by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Anti-VEGF Agents Drug Class, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$34.3 ... Read More
-
Multiple Myeloma Therapeutics
... by 2030, growing at a CAGR of 14.6% over the analysis period 2023-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$37.6 ... Read More
-
Antibacterial Drugs
... at a CAGR of 3.9% over the analysis period 2023-2030. ß-lactams Drug Class, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end ... Read More
-
Pediatric Drugs and Vaccines
... reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach ... Read More
-
e-Prescription Systems
... at a CAGR of 17.0% over the analysis period 2023-2030. e-Prescription Solutions, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$3.2 Billion by the end of ... Read More
-
Anemia Drugs
... at a CAGR of 4.1% over the analysis period 2023-2030. Iron Deficiency Anemia Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the ... Read More
-
Prescription Drugs
... at a CAGR of 5.7% over the analysis period 2023-2030. Generics, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$498.0 Billion by the end of the ... Read More
-
Global Age-Related Macular Degeneration Market Forecast Report by Disease Type (Dry Age-Related Macular Degeneration Market, Wet Age-Related Macular Degeneration Market) Product (Eylea, Lucentis, Beovu, Others) Distribution Channel (Hospital Pharmacy, Specialty Pharma, Online Pharmacy) Countries and Company Analysis, 2024-2032
... Company Analysis, 2024-2032 Age-Related Macular Degeneration Market Analysis The Global Age-Related Macular Degeneration market is forecasted to reach US$ 19.53 billion by 2032 from US$ 10.68 billion in 2023, and compound annual growth rate of ... Read More
-
Active Pharmaceutical Ingredients (API)
... reach US$358.5 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Innovative API, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach ... Read More
-
Anti-Obesity Drugs
... at a CAGR of 8.7% over the analysis period 2023-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of ... Read More
-
Antibiotics
... of 3.1% over the analysis period 2023-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth ... Read More
-
Human Growth Hormone Drugs
... reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach ... Read More
-
Pain Management Drugs Market By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033
... Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033 Pain Management Drugs Market The pain management drugs market was valued at $72.6 billion in 2023 ... Read More
-
Acute Coronary Syndrome
... by 2030, growing at a CAGR of 10.5% over the analysis period 2023-2030. The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 16.4% CAGR The Acute Coronary Syndrome market ... Read More
-
Anti-Hypertensive Drugs
... at a CAGR of 2.8% over the analysis period 2023-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end ... Read More
-
Migraine Drugs
... at a CAGR of 16.1% over the analysis period 2023-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$7.2 Billion by the end of ... Read More
-
Tuberculosis Therapeutics
... at a CAGR of 2.7% over the analysis period 2023-2030. Active TB Therapeutics, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end ... Read More
-
Growth Hormone Deficiency Market Size, Share & Segmentation, by Type, by Indication, by Distribution Channel, By Regions | Global Market Forecast 2024-2031
... insights into a specific market, industry, or sector. It involves the systematic collection, analysis, and interpretation of data related to market conditions, consumer behaviors, competitive landscapes, and emerging trends. The primary purpose of a market ... Read More
-
Global Osteoporosis Drugs Market Report by Route of Administration (Injectable, Oral, Others) Product Type (Rank Ligand Inhibitor, Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, Others) Countries and Company Analysis, 2024-2032
... 2024-2032 Osteoporosis Drugs Market Analysis The osteoporosis drugs market is expected to over US$ 25.53 billion by 2032 from US$ 17.43 billion by 2023, with a CAGR growth of 4.33% from 2024 to 2032 because ... Read More
-
Anti-Infectives
... of 6.2% over the analysis period 2023-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. ... Read More
-
Global Antacids Market Report by Formulation Type (Powder, Tablets, Liquid, Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Drug Class (Acid Neutralizers, Proton Pump Inhibitors, H2 Antagonist, Pro-Motility Agents) Countries and Company Analysis, 2024-2032
... Global Antacids Market Size Global antacids Market will be expected to cross US$ 9.70 billion by 2032 with a CAGR of 3.89 from 2024 to 2032. This growth has been fostered by the rising incidence ... Read More
-
Herpes Simplex Virus Infections
... reach US$6.6 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030. The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR The Herpes ... Read More
Research Assistance
